Omeros Corporation Common Stock OMER
i
Market dataready · fetched 2026-11-07T07:30:57.554Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T23:54:10.15487683Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-07T07:30:57.021580+00:00
Omeros Corporation Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 14.63 | 105.8% | 16.6% | |||
| 25Δ | 15.08 | 111.2% | 14.9% | |||
| 30Δ | 19.44 | 110.8% | 18.0% | 15.54 | 115.4% | 13.4% |
| 35Δ | 18.85 | 110.0% | 15.3% | 16.01 | 119.5% | 11.9% |
| 40Δ | 18.36 | 110.7% | 13.3% | 16.49 | 120.0% | 10.5% |
| 45Δ | 17.87 | 110.9% | 11.4% | 16.98 | 120.4% | 9.0% |
| 50Δ | 17.41 | 109.7% | 9.7% | 17.48 | 120.7% | 7.8% |
| 55Δ | 16.94 | 109.0% | 8.1% | 17.98 | 121.0% | 6.7% |
| 60Δ | 16.49 | 111.1% | 7.0% | 18.43 | 116.3% | 5.5% |
| 65Δ | 16.04 | 113.3% | 5.8% | 18.87 | 111.4% | 4.3% |
| 70Δ | 19.17 | 103.2% | 3.4% | |||
| 75Δ | 14.56 | 159.9% | 5.6% | |||
| 80Δ | 14.00 | 147.4% | 3.7% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.63
- IV
- 105.8%
- B/E move
- 16.6%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 15.08
- IV
- 111.2%
- B/E move
- 14.9%
30Δ
- Pseudo strike
- 19.44
- IV
- 110.8%
- B/E move
- 18.0%
- Pseudo strike
- 15.54
- IV
- 115.4%
- B/E move
- 13.4%
35Δ
- Pseudo strike
- 18.85
- IV
- 110.0%
- B/E move
- 15.3%
- Pseudo strike
- 16.01
- IV
- 119.5%
- B/E move
- 11.9%
40Δ
- Pseudo strike
- 18.36
- IV
- 110.7%
- B/E move
- 13.3%
- Pseudo strike
- 16.49
- IV
- 120.0%
- B/E move
- 10.5%
45Δ
- Pseudo strike
- 17.87
- IV
- 110.9%
- B/E move
- 11.4%
- Pseudo strike
- 16.98
- IV
- 120.4%
- B/E move
- 9.0%
50Δ
- Pseudo strike
- 17.41
- IV
- 109.7%
- B/E move
- 9.7%
- Pseudo strike
- 17.48
- IV
- 120.7%
- B/E move
- 7.8%
55Δ
- Pseudo strike
- 16.94
- IV
- 109.0%
- B/E move
- 8.1%
- Pseudo strike
- 17.98
- IV
- 121.0%
- B/E move
- 6.7%
60Δ
- Pseudo strike
- 16.49
- IV
- 111.1%
- B/E move
- 7.0%
- Pseudo strike
- 18.43
- IV
- 116.3%
- B/E move
- 5.5%
65Δ
- Pseudo strike
- 16.04
- IV
- 113.3%
- B/E move
- 5.8%
- Pseudo strike
- 18.87
- IV
- 111.4%
- B/E move
- 4.3%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 19.17
- IV
- 103.2%
- B/E move
- 3.4%
75Δ
- Pseudo strike
- 14.56
- IV
- 159.9%
- B/E move
- 5.6%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 14.00
- IV
- 147.4%
- B/E move
- 3.7%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 75.99% | |
| 71.20% | |
| 71.84% | |
| 73.29% | |
| 71.39% | |
| 70.58% | |
| 71.56% | |
| 70.08% | |
| 73.71% | |
| 72.78% |
Biotechnology
ONC
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The…
More →ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. The company is headquartered in South San…
More →ORKA
Oruka Therapeutics, Inc. is a biotechnology company.
More →ORMP
Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or…
More →OTLK
Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The company…
More →OVID
Description unavailable
More →